Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers - Lung Cancer
Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. | Semantic Scholar
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology | Laboratory Investigation
![PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/df73d74a72129de1592255fc0a74db3d4b45eef3/2-Figure1-1.png "PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar")
PDF] MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life | Semantic Scholar
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations Rafael Caparica, MD, - ppt download
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study Yu Y, Zhang Q, Zhang J, Lu S - J Can Res Ther
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment - Journal of Thoracic Oncology
Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib
A) Kaplan–Meier survival curves for relapse free according to MET exon... | Download Scientific Diagram
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
References in Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - Journal of Thoracic Oncology
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping - Journal of Thoracic Oncology
METex14 in non-small lung cancers. (a) schematic diagram of genomic... | Download Scientific Diagram
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Progression-free survival by MET exon 14 alteration detection in... | Download Scientific Diagram
Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib - Journal of Thoracic Oncology
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
